Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Hanmi Science Co., Ltd. (008930:KRX), powered by AI.
Hanmi Science Co., Ltd. is currently trading at ₩38,550. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Hanmi Science Co., Ltd. on Alpha Lenz.
Hanmi Science Co., Ltd.'s P/E ratio is 43.9.
“Hanmi Science Co., Ltd. trades at a P/E of 43.9 (premium valuation) with modest ROE of 7.3%. 3Y revenue CAGR of 10.5% highlights clear growth momentum.”
Ask for details →Hanmi Science Co., Ltd. is a prominent South Korean company engaged in the pharmaceutical and biotechnology sectors, with a focus on developing innovative healthcare solutions. As the holding company of Hanmi Pharmaceuticals, its primary function is to drive drug discovery and ensure the availability of effective medical products. Hanmi Science undertakes research and development activities, emphasizing biopharmaceuticals and chemical drugs, particularly in areas like oncology, diabetes, and autoimmune diseases. The company plays a vital role in the healthcare industry by advancing medical research and contributing to improving public health outcomes. Operating as a key player within the biotechnology market, Hanmi Science influences the proliferation of cutting-edge therapies and medicines, both in South Korea and internationally. Its commitment to innovation and therapeutic advancements has positioned it as a critical contributor to the global pharmaceuticals landscape, impacting not only direct healthcare provision but also broader industry research collaborations and partnerships.
“Hanmi Science Co., Ltd. trades at a P/E of 43.9 (premium valuation) with modest ROE of 7.3%. 3Y revenue CAGR of 10.5% highlights clear growth momentum.”
Ask for details →Hanmi Science Co., Ltd. (ticker: 008930) is a company listed on KRX in the Healthcare sector (Medical Distribution). It has approximately 443 employees. Market cap is $2.6T.
The current price is ₩38,550 with a P/E ratio of 43.93x and P/B of 3.1x.
ROE is 7.30% and operating margin is 2.96%. Annual revenue is $1.3T.